Logo image of TCRR

TCR2 THERAPEUTICS INC (TCRR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TCRR - US87808K1060 - Common Stock

1.48 USD
-0.09 (-5.73%)
Last: 5/31/2023, 8:00:02 PM
1.53 USD
+0.05 (+3.38%)
After Hours: 5/31/2023, 8:00:02 PM
Fundamental Rating

2

Overall TCRR gets a fundamental rating of 2 out of 10. We evaluated TCRR against 530 industry peers in the Biotechnology industry. While TCRR seems to be doing ok healthwise, there are quite some concerns on its profitability. TCRR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TCRR had negative earnings in the past year.
In the past year TCRR has reported a negative cash flow from operations.
TCRR had negative earnings in each of the past 5 years.
TCRR had a negative operating cash flow in each of the past 5 years.
TCRR Yearly Net Income VS EBIT VS OCF VS FCFTCRR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

TCRR has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TCRR Yearly ROA, ROE, ROICTCRR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TCRR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCRR Yearly Profit, Operating, Gross MarginsTCRR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

TCRR has more shares outstanding than it did 1 year ago.
TCRR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TCRR Yearly Shares OutstandingTCRR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
TCRR Yearly Total Debt VS Total AssetsTCRR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

TCRR has an Altman-Z score of -6.44. This is a bad value and indicates that TCRR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TCRR (-6.44) is worse than 70.08% of its industry peers.
There is no outstanding debt for TCRR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.44
ROIC/WACCN/A
WACCN/A
TCRR Yearly LT Debt VS Equity VS FCFTCRR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

TCRR has a Current Ratio of 2.96. This indicates that TCRR is financially healthy and has no problem in meeting its short term obligations.
TCRR has a worse Current ratio (2.96) than 69.28% of its industry peers.
TCRR has a Quick Ratio of 2.96. This indicates that TCRR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TCRR (2.96) is worse than 68.16% of its industry peers.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
TCRR Yearly Current Assets VS Current LiabilitesTCRR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for TCRR have decreased strongly by -49.47% in the last year.
EPS 1Y (TTM)-49.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TCRR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.12% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.95%
EPS Next 2Y25.45%
EPS Next 3Y17.13%
EPS Next 5Y16.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TCRR Yearly Revenue VS EstimatesTCRR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 100M 200M 300M
TCRR Yearly EPS VS EstimatesTCRR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TCRR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TCRR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCRR Price Earnings VS Forward Price EarningsTCRR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCRR Per share dataTCRR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

TCRR's earnings are expected to grow with 17.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.45%
EPS Next 3Y17.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TCRR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TCR2 THERAPEUTICS INC

NASDAQ:TCRR (5/31/2023, 8:00:02 PM)

After market: 1.53 +0.05 (+3.38%)

1.48

-0.09 (-5.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-11 2023-05-11/bmo
Earnings (Next)08-07 2023-08-07/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners9.57%
Ins Owner Change0%
Market Cap58.11M
Revenue(TTM)N/A
Net Income(TTM)-163.10M
Analysts73.33
Price Target5.86 (295.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-70.94%
Min EPS beat(2)-93.38%
Max EPS beat(2)-48.5%
EPS beat(4)1
Avg EPS beat(4)-34.1%
Min EPS beat(4)-93.38%
Max EPS beat(4)7.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.37%
PT rev (3m)-41.98%
EPS NQ rev (1m)-34.75%
EPS NQ rev (3m)0.13%
EPS NY rev (1m)0%
EPS NY rev (3m)7.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-4.2
EYN/A
EPS(NY)-1.68
Fwd EYN/A
FCF(TTM)-3.16
FCFYN/A
OCF(TTM)-2.81
OCFYN/A
SpS0
BVpS2.58
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 461.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.96
Altman-Z -6.44
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)454.2%
Cap/Depr(5y)411.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.53%
EPS Next Y42.95%
EPS Next 2Y25.45%
EPS Next 3Y17.13%
EPS Next 5Y16.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.65%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-81.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.19%
OCF growth 3YN/A
OCF growth 5YN/A

TCR2 THERAPEUTICS INC / TCRR FAQ

What is the fundamental rating for TCRR stock?

ChartMill assigns a fundamental rating of 2 / 10 to TCRR.


Can you provide the valuation status for TCR2 THERAPEUTICS INC?

ChartMill assigns a valuation rating of 3 / 10 to TCR2 THERAPEUTICS INC (TCRR). This can be considered as Overvalued.


How profitable is TCR2 THERAPEUTICS INC (TCRR) stock?

TCR2 THERAPEUTICS INC (TCRR) has a profitability rating of 1 / 10.


Can you provide the financial health for TCRR stock?

The financial health rating of TCR2 THERAPEUTICS INC (TCRR) is 3 / 10.